Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Anti-HVEM mAb therapy improves antitumoral immunity both in vitro and in vivo, in a novel transgenic mouse model expressing human HVEM and BTLA molecules challenged with HVEM expressing tumors

Background Tumor necrosis factor superfamily member 14 (TNFRSF14)/herpes virus entry mediator (HVEM) is the ligand for B and T lymphocyte attenuator (BTLA) and CD160-negative immune co-signaling molecules as well as viral proteins. Its expression is dysregulated with an overexpression in tumors and...

Full description

Bibliographic Details
Main Authors: Fabrice Barlesi, Laurent Gorvel, Daniel Olive, Clemence Demerle, Laurent Greillier, Sonia Pastor, Geoffrey Guittard, Jacques A Nunes, Marielle Mello, Clara Degos, Ana Zarubica, Fabien Angelis, Frédéric Fiore, Bernard Malissen, Hervé Luche
Format: Article
Language:English
Published: BMJ Publishing Group 2023-05-01
Series:Journal for ImmunoTherapy of Cancer
Online Access:https://jitc.bmj.com/content/11/5/e006348.full

Internet

https://jitc.bmj.com/content/11/5/e006348.full

Similar Items